We are live on ! Find out more
CASC

Cascadian Therapeutics, Inc.
CASC

Delisted

CASC was delisted on the 8th of March, 2018.

Back to rankings

76 hedge funds and large institutions have $142M invested in Cascadian Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 19 increasing their positions, 20 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

221% more call options, than puts

Call options by funds: $273K | Put options by funds: $85K

69% more capital invested

Capital invested by funds: $84.3M → $142M (+$58.1M)

25% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 8

1% more funds holding

Funds holding: 75 → 76 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 20

Holders
76
Holders Change
+1
Holders Change %
+1.33%
% of All Funds
2.03%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
10
Increased
19
Reduced
20
Closed
8
Calls
$273K
Puts
$85K
Net Calls
+$188K
Net Calls Change
+$149K

Top Buyers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
+$683K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$296K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$177K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$174K
5
EWM
Edge Wealth Management
New York
+$118K

Top Sellers

Rank Fund Capital Flow
1
EAM
EverPoint Asset Management
Connecticut
-$827K
2
SM
Sabby Management
Florida
-$739K
3
CS
Credit Suisse
Switzerland
-$399K
4
PP
Paloma Partners
Connecticut
-$337K
5
AFM
Anson Funds Management
Texas
-$308K
Name Holding Trade Value Shares
Change 		Change in
Stake
TI
26
Telemetry Investments
New York
$233K -$128K -18,000 -43%
VKH
27
Virtu KCG Holdings
New York
$226K +$109K +15,425 +205%
Jacobs Levy Equity Management
28
Jacobs Levy Equity Management
New Jersey
$189K -$172K -24,300 -56%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$176K -$18.8K -2,648 -13%
BCM
30
Bridgeway Capital Management
Texas
$172K +$10.9K +1,534 +10%
EWM
31
Edge Wealth Management
New York
$164K +$118K +16,667 New
Connor, Clark & Lunn Investment Management (CC&L)
32
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$156K – – –
ProShare Advisors
33
ProShare Advisors
Maryland
$140K +$17K +2,396 +20%
Stifel Financial
34
Stifel Financial
Missouri
$137K – – –
LTFS
35
Ladenburg Thalmann Financial Services
Florida
$133K – – –
OAM
36
Oxford Asset Management
United Kingdom
$133K +$21.2K +2,995 +28%
D.E. Shaw & Co
37
D.E. Shaw & Co
New York
$128K -$12.9K -1,820 -12%
State Street
38
State Street
Massachusetts
$109K – – –
TSS
39
Two Sigma Securities
New York
$82K +$58.9K +8,305 New
TRCT
40
Tower Research Capital (TRC)
New York
$81K +$2.42K +341 +4%
Tudor Investment Corp
41
Tudor Investment Corp
Connecticut
$80K – – –
UBS Group
42
UBS Group
Switzerland
$71K +$51.2K +7,217 New
Group One Trading
43
Group One Trading
Illinois
$59K +$42.7K +6,022 New
Wolverine Trading
44
Wolverine Trading
Illinois
$55K +$42.3K +5,965 New
DADC
45
D.A. Davidson & Co
Montana
$52K +$1.42K +200 +4%
IWA
46
Intercontinental Wealth Advisors
Texas
$49K – – –
GCP
47
GSA Capital Partners
United Kingdom
$49K +$35.1K +4,950 New
CS
48
Credit Suisse
Switzerland
$47K -$399K -56,306 -92%
Charles Schwab
49
Charles Schwab
California
$43K – – –
Citigroup
50
Citigroup
New York
$37K +$12.4K +1,751 +88%
1
2
3 4

CASC Hedge Fund Activity: Q3 2016 in Review

76 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q3 2016, worth a combined $142M — up 69% from $84.3M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new CASC positions and 8 closed out — a net gain of 2 holders — while 19 added to existing stakes and 20 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $683K. The largest seller was EverPoint Asset Management, cutting an estimated $827K.

  • 76 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q3 2016, up from 75 in Q2 2016.
  • Funds reported $142M of Cascadian Therapeutics, Inc. stock for Q3 2016, up 69% quarter-over-quarter.
  • 10 funds opened new Cascadian Therapeutics, Inc. positions in Q3 2016 and 8 closed out, a net change of +2 holders.
  • The largest Cascadian Therapeutics, Inc. buyer in Q3 2016 was BlackRock Fund Advisors, an estimated $683K added.
  • The largest Cascadian Therapeutics, Inc. seller in Q3 2016 was EverPoint Asset Management, an estimated $827K sold.

Based on aggregated 13F filings for Q3 2016.